Europe Measles Mumps And Rubella Vaccines Market Size & Outlook
Related Markets
Europe measles mumps and rubella vaccines market highlights
- The Europe measles mumps and rubella vaccines market generated a revenue of USD 517.3 million in 2024.
- The market is expected to grow at a CAGR of 8.8% from 2025 to 2030.
- In terms of segment, tetravalent was the largest revenue generating type in 2024.
- Tetravalent is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Denmark is expected to register the highest CAGR from 2025 to 2030.
Europe data book summary
| Market revenue in 2024 | USD 517.3 million |
| Market revenue in 2030 | USD 852.1 million |
| Growth rate | 8.8% (CAGR from 2025 to 2030) |
| Largest segment | Tetravalent |
| Fastest growing segment | Tetravalent |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monovalent, Trivalent (combined MMR), Tetravalent |
Other key industry trends
- In terms of revenue, Europe region accounted for 28.4% of the global measles mumps and rubella vaccines market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 647.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Measles Mumps and Rubella Vaccines Market Scope
Measles Mumps and Rubella Vaccines Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Beijing Tiantan Biological Products | View profile | 1-10 | Beijing, Beijing, China, Asia | http://www.tiantanbio.com |
| Shanghai Institute of Biological Products | View profile | 1001-5000 | Shanghai, Shanghai, China, Asia | http://www.siobp.com/ |
| Biological E. | View profile | 1001-5000 | Hyderabad, Andhra Pradesh, India, Asia | http://www.biologicale.com |
| Sinovac Biotech Ltd | View profile | 3261 | No.39, Shangdi Xi Road, Haidan District, Beijing, China, People's Republic of, 100085 | http://www.sinovac.com |
| Serum Institute of India Pvt. Ltd. | View profile | 1001-5000 | Pune, Maharashtra, India, Asia | http://www.seruminstitute.com/ |
| GSK PLC | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
Europe measles mumps and rubella vaccines market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to measles mumps and rubella vaccines market will help companies and investors design strategic landscapes.
Tetravalent was the largest segment with a revenue share of 62.19% in 2024. Horizon Databook has segmented the Europe measles mumps and rubella vaccines market based on monovalent, trivalent (combined mmr), tetravalent covering the revenue growth of each sub-segment from 2018 to 2030.
The European measles, mumps, and rubella vaccines market is experiencing steady growth, driven by comprehensive immunization programs and strong healthcare infrastructure. The region benefits from extensive public health policies and EU-wide vaccination efforts that promote MMR immunization.
However, challenges such as vaccine hesitancy and economic disparities in certain areas, particularly Eastern Europe, persist. Despite these challenges, Europe continues to make progress in combating these diseases, with v0accination rates generally exceeding 90% in most countries.
Reasons to subscribe to Europe measles mumps and rubella vaccines market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe measles mumps and rubella vaccines market databook
-
Our clientele includes a mix of measles mumps and rubella vaccines market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe measles mumps and rubella vaccines market , including forecasts for subscribers. This continent databook contains high-level insights into Europe measles mumps and rubella vaccines market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe measles mumps and rubella vaccines market size, by country, 2018-2030 (US$M)
Europe Measles Mumps and Rubella Vaccines Market Outlook Share, 2024 & 2030 (US$M)
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
